Nicole Lambert - 21 Sep 2021 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.
Signature
By: Nathan A. Smith For: Nicole Lambert
Issuer symbol
MYGN
Transactions as of
21 Sep 2021
Net transactions value
$0
Form type
4
Filing time
23 Sep 2021, 17:24:40 UTC
Previous filing
30 Aug 2021
Next filing
27 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Award $0 +65,870 +52% $0.000000 192,921 21 Sep 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.

Remarks:

Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.